MiniMed[™] 780G system

with Simplera Sync™ sensor

Proven to succeed in improving clinical outcomes and quality of life^{1,*}




MiniMed[™] 780G system automatically adjusts** & corrects glucose levels every 5 minutes, as needed

SmartGuard[™] technology uses the target settings to automatically deliver basal insulin and auto correction doses every 5 minutes, based on sensor glucose readings.

The MiniMed[™] 780G system is outfitted with several modules for safety and efficacy.





1 Autocorrections

These can be delivered as frequently as every 5 minutes, to mitigate hyperglycaemia, to help keep blood glucose in tighter control.

2 Meal detection

If a pattern of rising glucose indicates that a meal has been eaten, the system can automatically deliver stronger correction doses, bringing glucose levels safely back into range.

3 Safe meal bolus

This is a safety feature that will reduce the amount of meal bolus insulin if the system predicts hypoglycaemia would occur if the full bolus was given.


Please refer to MiniMed™ 780G system IFU. These features do not replace the need to bolus before meals.



Proven to improve glucose control in a wide range of T1D population^{1-4,†}

MiniMed[™] 780G system real-world evidence

+100K users of the MiniMed[™] 780G system have globally demonstrated consistency in achieving target control of glycemia, sustained over the 12 months observation period.²



	All users	Optimal setting users ^{††}
Number of users, n	101,629	6,531
Time in SmartGuard™, %	90.1	94.5
Mean SG, mg/dL (mmol/L)	152.0 (8.4)	140.4 (7.9)
GMI, %	7.0	6.7
Percentage of users achieving glycaemic targets GMI < 7%, %	59.6	85.0
Percentage of users achieving glycaemic targets TIR > 70%, %	62.5	86.3


Recommended SmartGuard[™] settings Glucose Target: 100mg/dL (5.5mmol/L) AIT (Active Insulin Time): 2 hours

me in Ranges, % 54 70 180 250 mg/dL 3.0 3.9 10.0 13.9 mmol/L

A glucose target of 100mg/dL (5.5mmol/L) and active Insulin Time (AIT) of 2 hours are recommended to reach optimal outcomes

Proven to improve user experience and quality of life^{1,5}

Transitioning from MDI and SMBG directly to MiniMed™ 780G system can improve the wellbeing of PWT1D, giving them more comfort, freedom, and life flexibility.⁵



Using this system was the 1st time in my life I have been able to switch off my mind all the thoughts about control & treatment. I did not know how much mental space this took until I didn't have to."[‡]

4

System components



Innovation that transforms lives

Our comprehensive care is **more than just a device**. We offer **personalised assistance** beyond technology **for you and your patients** so they always feel supported while **you save time and effort** in your care and research.

Services for Healthcare Professionals

Helping you give the best care to all your patients

Professional support and development	Easy access to education & resources	Efficient daily care	Improving your patients' treatment effectiveness
Diabetes Medical Education	WePartner Online	Connect	Galaxy
Delivering education. Inspiring excellence. Advancing your patient care.	The online platform that makes patient management easier for you.	Prioritise your time through an intuitive triaging tool.	Collect and analyse your patients' data to conduct influential research.
Access the Medtronic Academy website here:	Register here:	View the brochure:	View the brochure:
Nurse+		Data Interoperability	
Co-create education materials, process your career, exchange with your peers.		Make patients' device data available directly to your hospital primary medical record.	

Services for people living with diabetes

Helping live a life as burden-free as possible



MiniMed[™] 780G system

with Simplera Sync[™] sensor



References:

- Compared with MiniMed 640G system
- Refer to System User Guide SmartGuard™ feature. Some user interaction required
- † The MiniMed™ 780G insulin pump is indicated for use by patients age 7-80 years with Type 1 diabetes
- Optimal settings = Glucose Target: 100 mg/dL (5.5mmol/L) Active Insulin Time (AIT): 2 hours used for at least 95% of the time
- The patients testimonials relates an account of an individua's response to the treatment. The account is genuine, typical and documented. However, the individual's response does not provide any indication, guide, warranty or guarantee as to the response other patients may have to the treatment. The response other patients have to the treatment could be different. Responses to the treatment discussed can and do vary and specific to the individual patient.
- When used with Medtronic Extended infusion set, Refer to User Guide
- §§ A blood glucose (BG) reading is needed when entering SmartGuard™ feature. If glucose alerts and CGM readings do not match your symptoms, use a BG meter to make diabetes treatment decisions
- Compared to MDI + isCGM
- Choudhary P, et al. Lancet Diabetes Endocrinol. 2022;10(10):720-731.
- 2. Choudhary P, et al. Diabetes Technol Ther 2024; 26 (Supplement 3): \$32-\$37 Doi: 10.1089/dia.2023.0433.80% TIR is reached using the recommend optimal settings
- Carlson AL, et al. Diabetes Technol Ther.2022;24(3):178-189.
- 4. Matejko B, et al. Diabetes Care 2022;45:2628-2635
- Cyranka K, et al. JMIR Form Res. 2023;7:e43535. doi: 10.2196/43535 validated questionnaire used: Global QoL, State-Trait Anxiety Inventory STAI
- llany J, et al. Abstract 416 at the 13th ATTD International Conference. February 2020.

Brief statement:

© Medtronic 2024. All rights reserved. Medtronic and the Medtronic logo are trademarks of Medtronic. TM* Third party brands are trademarks of their respective owners. All other brands are trademarks of a Medtronic company.

ACCU-CHECK AND ACCU-CHEK GUIDE LINK are trademarks of Roche Diabetes Care. For detailed information regarding the instructions for use, indications, contraindications, warnings, precautions, and potential adverse events, please consult the device manual. For further information, contact your local Medtronic representative.

DreaMed Diabetes is a trademark of DreaMed Diabetes, Ltd. The MiniMed 780G system algorithm includes technology developed by DreaMed Diabetes.

Medtronic

Medtronic International Trading Sàrl. Route du Molliau 31 Case postale CH-1131 Tolochenaz www.medtronic.eu Tel: +41 (0)21 802 70 00 Fax: +41 (0)21 802 79 00

United Kingdom/Ireland

Medtronic Limited Building 9, Croxley Park Hatters Lane, Watford Herts WD18 8WW www.medtronic.co.uk Tel: +44 (0)1923 212213 Fax: +44 (0)1923 241004

